EMA celebrates 25 years advancing public and animal health
“25 years is a significant milestone for EMA. Together with our partners and stakeholders from national authorities, EU institutions and civil society we harmonised and improved medicines’ evaluation, stimulated innovation, improved safety monitoring and management, fostered transparency and dialogue, built relationships with international partners, and helped to make medicines accessible to those who need them’’, said Guido Rasi, EMA's Executive Director. “As we look to the future, we will continue to build on these strong foundations to deliver high-quality work for the benefit of public and animal health’’.
Founded in 1995, EMA has worked across the EU and globally to protect public and animal health by assessing medicines to rigorous scientific standards and by providing partners and stakeholders with independent, science-based information on medicines.
EMA's success is based on cooperation within the European medicines regulatory network – a unique partnership between the European Commission, the medicines regulatory authorities in the European Economic Area countries, and EMA. Working together with stakeholders, including patients, healthcare professionals, industry representatives, academia and other experts has encouraged the exchange of knowledge, ideas and best practices, in order to ensure the highest standards in medicines regulation.
Seven EMA scientific committees provide scientific expertise for the regulation of medicines by drawing on a pool of several thousand European scientific experts from the network.
The Agency's remit has expanded over time, in line with new EU legislation. On top of its remit to evaluate human and veterinary medicines, EMA is also responsible for products developed in the specialised areas of medicines for rare diseases (since 2000), herbal medicines (since 2004), medicines for children (since 2006) and advanced-therapy medicines (since 2007).
Working with patients and healthcare professionals has been instrumental for EMA from the outset. In 2000, patient representatives joined for the first time as members of one of EMA’s scientific committees (the Committee for orphan medicines). Today, their representatives take part in most of EMA's scientific committees as full members, adding their unique perspective and experiences to discussions. They play an increasingly important role in the assessment of the risks and benefits of medicines.
An overview of key milestones and achievements in the authorisation and safety monitoring of medicines for human and animal use in the EU is published.